Pfizer Inc. (PFE) is in the Pharma Industry

• Sort by
• View by Content Type
• View Related Content by Tag

• Drugmakers Need to Rein in Ads, Hearing Told

  By Susan Heavey WASHINGTON (Reuters) - Pharmaceutical companies need to be more responsible in touting products to consumers or else face tighter controls from Congress, a top U.S. Democratic lawmaker said on Thursday. Rep. Bart Stupak, at a hearing to discuss specific ads...

  News items 2008-05-08

  Tags: Schering-Plough Corp., Pfizer Inc., Merck & Co. Inc., pharmaceutical company, drug company, patient, advertisement, physician, U.S. Congress, Washington, risk, TV, Thomson Reuters Corp., food, benefit, knowledge, technique, sales, marketing

• Pfizer Drops Glaucoma Drug, NicOx Shares Slump

  PARIS (Reuters) - Pfizer PFE has decided not to take NicOx's NCOX experimental glaucoma drug PF-03187207 into final Phase III tests after a mid-stage study failed to met its primary endpoint, sending NicOx shares tumbling. The news is a major blow for NicOx,...

  News items 2008-05-06

  Tags: Pfizer Inc., endpoint, compound, Paris, biotechnology, Thomson Reuters Corp., patient, collaboration

• Pfizer Reaches Deal With Some Celebrex Users: Report

  NEW YORK (Reuters) - Pfizer Inc PFE has reached tentative deals with some patients who claim to have suffered heart attacks and strokes from taking the company's Celebrex and Bextra pain medicines, the Wall Street Journal said on Friday, citing plaintiff...

  News items 2008-05-02

  Tags: Pfizer Inc., law firm, attorney, patient, pending litigation, lawyer, New York, advisor, litigation, Thomson Reuters Corp., benefit

• Pfizer Invests $300 Mln in Irish Biotech Facility

  LONDON (Reuters) - Pfizer Inc PFE, the world's biggest drugmaker, is to invest 190 million euros ($297 million) establishing a new biotech plant in Ireland for the production of experimental medicines, it said on Friday. The facility, which will create around 100 permanent...

  News items 2008-05-02

  Tags: Pfizer Inc., drug company, biotechnology, Ireland, London, clinical trial, Thomson Reuters Corp., manufacturing, leader, job

• Esperion Escapes the Pfizer Borg

  Esperion Therapeutics, a biotech that Pfizer spent $1.3 billion acquiring in 2003, is free once more. And its founder, Roger Newton, is apparently putting the band back together. Newton, in fact, has just pulled off one of the rarer and most complicated moves in biotechnology -- the...

  Blog posts 2008-05-01

  Tags: Pfizer Inc., Esperion, Biotechnology, Mergers & Acquisitions, Investment, Finance, David P. Hamilton

• Drugmakers Win Appeal Over Alzheimer Curbs

  By Ben Hirschler LONDON (Reuters UK) - An appeals court on Thursday ruled the country's healthcare cost-effectiveness watchdog had acted unfairly in the way it decided to curb access to Alzheimer's drugs, in a victory for drugmakers and patients. The move will let manufacturers renew their...

  News items 2008-05-01

  Tags: Alzheimer's Disease, Patient, Health Care, NICE, QALY, Johnson & Johnson, Noven Pharmaceuticals Inc., Pfizer Inc.

• Glaxo Profits Fall as Avandia and Generics Weigh

  By Ben Hirschler LONDON (Reuters UK) - GlaxoSmithKline GSK profits fell 5 percent in the first quarter, hit by tumbling sales of diabetes drug Avandia and generic competition to other products, the world's second biggest drugmaker said. The decline was less than analysts had feared, helped...

  News items 2008-04-23

  Tags: Performance, Analyst, Avandia, Sales, AstraZeneca Plc., Glaxo, GlaxoSmithKline Plc., Noven Pharmaceuticals Inc., Pfizer Inc., Sirtris Pharmaceuticals Inc., US

• Glaxo Profit Fall as Generics Weigh

  By Ben Hirschler LONDON (Reuters) - GlaxoSmithKline Plc GSK profits fell 5 percent in the first quarter, hit by tumbling sales of diabetes drug Avandia and generic competition to other products, the world's second biggest drugmaker said. The decline was less than analysts...

  News items 2008-04-23

  Tags: Sales strategy, Sales force management, GlaxoSmithKline Plc., drug company, Security Incident Response Team, pharmaceutical company, sales, vaccine, Thomson Reuters Corp., London, analyst, wine, performance, earnings per share, operating profit, patient, acquisition, indu

• Pfizer Profit Misses Mark

  By Ransdell Pierson and Lewis Krauskopf NEW YORK (Reuters) - Pfizer Inc PFE on Thursday reported a worse-than-expected drop in quarterly earnings due to higher expenses and plunging U.S. sales of its cholesterol fighter Lipitor, sending its shares down almost 4 percent. The...

  News items 2008-04-17

  Tags: Research & Development, HEALTHCARE, Pfizer Inc., Merck & Co. Inc., clinical trial, drug company, R&D, blood pressure, New York, biotechnology, Thomson Reuters Corp., CEO, sales

• European Shares Down on Nokia and Pharma Stocks

  FRANKFURT (Reuters UK) - European shares fell on Thursday, led lower by Nokia (NOK1V) after the world's biggest maker of mobile phones failed to impress investors with its outlook, dragging down other technology and telecom stocks. The pan-European FTSEurofirst 300 index closed down 0.6...

  News items 2008-04-17

  Tags: Bank, Nokia Corp., Stock, Credit Agricole Official, UniCredit, AstraZeneca Plc., HBOS Plc., Merrill Lynch & Co. Inc., Pfizer Inc., Rogers Corp., Royal Dutch Shell Plc., STMicroelectronics

• Pfizer Leads in Layoffs While Drug Prices Soar

  Big Pharma continues to lend new meaning to the phrase "doing more with less," because while the industry seems to get smaller every day, drugmakers are still pushing through big price increases on their leading products. Over at Pharmalot, Ed Silverman provides a helpful roundup tracking the...

  Blog posts 2008-04-10

  Tags: Job, Layoff, Pfizer Inc., Drug Company, Industry, Drug, Sales Strategy, Strategy, Sales, Management, David P. Hamilton

• Bench, Bedside, and Beyond: Clinical Research at the Crossroads

  The opportunities for clinical research are enormous as are the challenges. The importance of nurturing clinical research has never been greater. Bio-molecular findings are bringing a new language of discovery. Clinical research lies at the nexus of basic biomedical research and clinical practice and is the portal through which the...

  White papers 2003-10-30

  Tags: Pfizer Inc., biomedical, portal

• Corporate Governance: Principles

  This article discusses Corporate Governance Principles for the investors. The various aspects which have been discussed in this article include: Role and Composition of the Board of Directors, Functioning of the Board and many other. All these have been discussed in detail in the article. Employees are required to report...

  White papers 2003-01-01

  Tags: Operational accounting, Pfizer Inc., auditing, accounting, business ethics, corporate governance, Sarbanes-Oxley Act, board

• Strategic FM Consulting for New Headquarters Sets the Standard for Global Pharmaceutical Company

  Pfizer is a global pharmaceutical company dedicated to discovering and developing innovative value-adding products, which improve the quality of life of people around the world. Supporting the in-house FM team to devise, develop and procure the facilities services needed to operate the building. Providing a dedicated Project Link role, working...

  Case studies

  Tags: Team management, Johnson Controls Inc., Pfizer Inc., team, strategy

• Case Study: University of Rochester v GD Searle &Co Inc & Ors

  The University of Rochester held a patent for methods of selectively inhibiting certain enzyme activity by administration of a non-steroidal compound. The defendants, associated companies Searle, Monsanto, Pharmacia, and Pfizer marketed selective enzyme inhibitors for the treatment of inflammation. The University brought an action for infringement against Pfizer, claiming the...

  Case studies

  Tags: Allens Arthur Robinson, Pfizer Inc., patent

• Manufacturing Phil: A Drug's Life

  A Pfizer public education campaign and its cute mascot are praiseworthy, but neglect to mention the key stage in a drug's life. What will it take to make manufacturing a hot button issue and to better educate the public? Given the current consumer and media backlash against drug makers, there's...

  White papers

  Tags: Pfizer Inc., manufacturing, tablet

Additional Resources

• Emiliem Expands Management Team With Industry Veterans Donna Romero and Diane Beuving

  KALAMAZOO, Mich. -- Emiliem, Inc., a privately-held biopharmaceutical company focused on discovering and developing novel molecular targeted therapeutics announced today that it has filled two key R&D positions on its management team. Donna Romero, Ph.D. joins Emiliem as VP, Chemical Sciences and Pharmaceutical Development with over 20 years...

  Articles 2008-05-07

• Zacks Analyst Blog Highlights: EnCana, MannKind, Pfizer, Eli Lilly and Novo Nordisk

  CHICAGO -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: EnCana (NYSE: ECA), MannKind (Nasdaq: MNKD), Pfizer (NYSE: PFE), Eli Lilly...

  Articles 2008-05-07

• Hershey Center for Applied Research Supports Acceleration of Scientific Research and Development

  Simon Revell, world-renowned Pfizer Enterprise 2.0 expert, to deliver keynote address at launch of ground-breaking social networking and scientific mapping online community HERSHEY, Pa., May 6 /PRNewswire/ -- Simon Revell, Manager of Enterprise 2.0 Technology Development at Pfizer , will discuss how Web 2.0 social software can...

  Articles 2008-05-06

• NicOx Announces U.S. Phase 2a Results for PF-03187207 and Gives an Update on Continuing NO-prostaglandin Program

  SOPHIA ANTIPOLIS, France, May 6 /PRNewswire-FirstCall/ -- NicOx S.A. (Euronext Paris: COX) today announced the results of a U.S. phase 2 study, conducted by its partner Pfizer Inc, which compared the safety and efficacy of various doses of PF-03187207 to XalatanR latanoprost 0.005% in patients with primary open-angle glaucoma...

  Articles 2008-05-06